The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialyis patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 12, 2004, Pages 3112-3116

  Nascimento, Marcelo M ^a,c,d   Suliman, Mohamed E ^d   Bruchfeld, Annette ^d   Hayashi, Shirley Y ^d   Manfro, Roberto C ^c   Qureshi, Abdul Rashid ^d   Pecoits Filho, Roberto ^b,d   Pachaly, Maria A ^a   Renner, Luciana ^a   Stenvinkel, Peter ^d   Riella, Miguel C ^a,b   Lindholm, Bengt ^d  

^a Faculdade Evangelica de Medicina   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ferritin; Haemodialysis; Hepatitis C; Oxidative stress; Pentosidine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; C REACTIVE PROTEIN; FERRITIN; INTERLEUKIN 6; IRON; PENTOSIDINE; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN;

ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; GENDER; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; SEROLOGY;

EID: 19944427971     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh508     Document Type: Article

References (23)

1. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
2. Suliman ME, Heimburger O, Barany P et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614-1622
3. Jadoul M, Ueda Y, Yasuda Y et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Kidney Int 1999; 55: 2487-2492
4. Carneiro MA, Martins RM, Teles SA et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001; 96: 765-769
5. Moriya K, Nakagawa K, Santa T et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-4370
6. Boya P, de la Pena A, Beloqui O et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999; 31: 808-814
7. Feldman HL Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
8. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-159
9. Miyata T, Ueda Y, Shinzato T et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-1206.
10. Wilker SC, Chellan P, Arnold BM, Nagaraj RH. Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins: comparison with pentosidine. Anal Biochem 2001; 290: 353-358
11. Miyata T, Fu MX, Kurokawa K et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54: 1290-1295
12. Koken T, Serteser M, Kahraman A, Gokce C. Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 2002; 15: 302-307
13. Hezode C, Cazeneuve C, Coue O et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999; 31: 979-984
14. Ishizaka Y, Ishizaka N, Takahashi E et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67: 26-30
15. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002; 13: 2783-2786
16. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
17. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
18. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
19. Kato A, Odamaki M, Nakamura H, Yodoi J, Hishida A. Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. Kidney Int 2003; 63: 2262-2268
20. Altintepe L, Kurtoglu E, Tonbul Z et al. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Clin Nephrol 2004; 61: 347-351
21. Sahin I, Arabaci F, Sahin HA et al. Does hepatitis C virus infection increase hematocrit and hemoglobin levels in hemodialyzed patients? Clin Nephrol 2003; 60: 401-404
22. Hinrichsen H, Leimenstoll G, Stegen G et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433
23. Bhagat CI, Fletcher S, Joseph J, Beilby JP. Plasma ferritin in acute hepatocellular damage. Clin Chem 2000; 46: 885-886